Vaxcyte, Inc. - Common Stock · Transaction Jul 16, 2026 · Filed Sep 4, 2026 · $1,001 to $15,000
XNAS · PCVX
+25.71% · +$14.52 · Vol 14.9M
After hours · updated 17:47:48 ET
Vaxcyte, Inc. Common Stock
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
$71.00
Follow $PCVX
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $PCVX by emailVeridion Score
BETAHIGH CONF · 6 of 6 factors measuredMon Oct 5 · session closed · Markets closed · resumes Tue 9:30 ET · PCVX
MethodologyPCVX
Vaxcyte, Inc. Common Stock
Mon Oct 5 · session closed · Markets closed · resumes Tue 9:30 ET
Upper range
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
66/ 100
Veridion Score
Upper range · HIGH confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6 of 6 factors measured · Mon Oct 5 · session closed · Markets closed · resumes Tue 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is PCVX moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Vaxcyte, Inc. Common Stock
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)Listed since
2020
Employees
507
Country
US
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$87.21
Day high
$90.75
Day low
$71.60
Previous close
$56.48
52W high
$90.75
-21.76% from high
52W low
$40.32
61% of range
Market cap
$8.4B
EPS
$-7.0500
Beta
1.21
Shares out
148.8M
Volume
14.9M
8.28× rel vol
Avg volume
1.8M
VWAP
$78.86
Price history computed in-house
1W
+21.85%
1M
+16.09%
3M
+17.03%
1Y
+66.43%
YTD
+53.88%
SMA 50 $58.92 · above
SMA 200 $55.29 · above
52W position 61%
PCVX overview
Related filings and maps
Public disclosures
Congress activity in PCVX
3 filers · 7 buys · 2 sells (0 labeled S (partial)) · Nov 8, 2022 to Jul 16, 2026 · House 9 / Senate 0
All available history · Latest 5 of 9 lines · Read 2026-10-05T21:48:41.873Z
Official filing ↗
Vaxcyte, Inc. - Common Stock · Transaction May 13, 2026 · Filed Jun 8, 2026 · $1,001 to $15,000
Vaxcyte, Inc. - Common Stock · Transaction May 12, 2026 · Filed Jun 8, 2026 · $1,001 to $15,000
Vaxcyte, Inc. - Common Stock · Transaction Apr 28, 2025 · Filed May 6, 2025 · $1,001 to $15,000
Vaxcyte, Inc. - Common Stock · Transaction Apr 15, 2025 · Filed May 6, 2025 · $1,001 to $15,000
Federal contracts
PCVX contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for PCVX in this window.
Lobbying spend
PCVX lobbying filings, year to date.
Registered lobbying filings matched to Vaxcyte, Inc. Common Stock.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for PCVX in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for PCVX.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.